CompletedNot Applicable

Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).

United States594 participantsStarted 2014-06

Plain-language summary

This Pilot study will enable development \& assessment of a Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q). Polycystic liver disease (PLD) is characterized by the formation of numerous cysts in the liver, and can lead to severe symptomatic hepatomegaly. It is common in patients with autosomal dominant polycystic liver disease (ADPLD) and autosomal dominant polycystic kidney disease (ADPKD).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients ≥ 18 year * Polycystic liver, defined by \> 20 liver cysts on imaging Exclusion Criteria: * Patients unable to speak or read the English properly * History of kidney or liver transplantation * Dialysis * Current use of experimental drugs (e.g. lanreotide, octreotide) * Recent liver resection or major surgery * Other comorbidities that can affect the outcome of the questionnaire, as deemed by the investigators

What they're measuring

Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q) total score

Timeframe: baseline to 6 months

Trial details

NCT IDNCT02173080

SponsorMayo Clinic

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-03-11

View on ClinicalTrials.gov More Polycystic Liver Disease trials